摘要
隨著胃酸相關疾病（acid-related disease）的盛行率逐漸增加與傳統氫離子幫浦阻斷劑（proton pump inhibitors, PPIs）的侷限性，新型鉀離子競爭性酸抑制劑（potassium-competitive acid blocker，P-CAB）能藉由競爭性阻斷氫離子幫浦（proton pump，H-K ATPase），提供相當甚至更好的治療效果。較傳統氫離子幫浦阻斷劑，新型鉀離子競爭性酸抑制劑能快速達到最大血中濃度，且半衰期長，與不受個體藥物代謝基因多樣性影響，對於治療胃潰瘍與十二指腸潰瘍、胃食道逆流、幽門螺旋桿菌除菌治療、預防胃食道逆流復發、因aspirin或NSAIDs引起的胃黏膜損傷、經內視鏡止血後的再出血都有相當的效果。
參考文獻
1. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656-65.
2. Xue S, Katz PO, Banerjee P, et al. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001;15:1351-6.
3. Ene MD, Khan-Daneshmend T, Roberts CJ. A study of the inhibitory effects of SCH 28080 on gastric secretion in man. Br J Pharmacol 1982;76:389-91.
4. Beil W, Hackbarth I, Sewing KF. Mechanism of gastric antisecretory effect of SCH 28080. Br J Pharmacol 1986;88:19-23.
5. Gedda K, Briving C, Svensson K, et al. Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+, K+-ATPase. Biochem Pharmacol 2007;73:198-205.